ClinicalTrials.gg
CompletedNCT02135302Updated Dec 17, 2021

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

A Phase 1 interventional study of eravacycline in Impaired Hepatic Function, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-17.

Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, open-label clinical study to assess the single-dose PK of eravacycline in subjects with hepatic impairment and healthy subjects conducted at approximately 3 sites in the United States. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (± 2 days) after initiation of study drug administration. Approximately 24 subjects will be enrolled: 18 subjects with impaired hepatic function (6 subjects who meet the criteria for each of the 3 Child-Pugh categories of mild [5 - 6 points], moderate [7 - 9 points], and severe [10 - 15 points]) and 6 healthy subjects without hepatic impairment. Healthy subjects will be matched to hepatically impaired subjects in gender, age, and body mass index (BMI). All subjects will be administered a single IV dose of eravacycline (1.5 mg/kg).

02

Conditions studied

  • Impaired Hepatic Function

Keywords

  • hepatic
03

In context

Lead sponsor

Tetraphase Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject aged ≥18 years at Screening;
  2. Eligible female subjects of with a non-sterilized male sexual partner must agree to use 2 medically accepted, effective methods of (eg, hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device) beginning >30 days prior to study drug administration and continuing until 7 days after the end of the study. Female subjects who are must have been postmenopausal for >1 year if they wish not to use contraceptives. If postmenopausal status is questionable, the subject's follicle-stimulating hormone level must be checked and must be elevated and consistent with postmenopausal levels (ie, >40 IU/L); otherwise these subjects must agree to use contraceptives listed above;
  3. Male subjects with sexual partners of childbearing potential must agree to use a barrier contraceptive from the time of study drug administration through 7 days after the end of the study;
  4. Female subjects of childbearing potential (including females with questionable postmenopausal status) must have a negative pregnancy test prior to dosing (Screening and Day -1);
  5. Has a of 17 kg/m2 to 40 kg/m2, inclusive;
  6. Has negative alcohol and illicit drug screens;
  7. Has a negative screen for (HIV);
  8. Is able to understand and comply with study procedures and give written according to institutional and regulatory guidelines;

    Subjects with hepatic impairment:

  9. Has a positive diagnosis of liver cirrhosis that has been stable for 2 months and is confirmed by imaging techniques, , or physical signs consistent with a clinical diagnosis of liver cirrhosis (eg, liver firmness to palpation, splenic enlargement, spider angiomata, palmar erythema, parotid hypertrophy, testicular atrophy, gynecomastia);
  10. Subjects with hepatic impairment must be categorized in 1 of the following:

    • Mild hepatic impairment: has impaired but stable hepatic function as evidenced by Clinical Assessment Score of 5-6 at both Screening and Day -1;
    • Moderate hepatic impairment: has impaired but stable hepatic function as evidenced by Child-Pugh Clinical Assessment Score of 7-9 at both Screening and Day -1; or
    • Severe hepatic impairment: has impaired but stable hepatic function as evidenced by Child-Pugh Clinical Assessment Score of 10-15 at both Screening and Day -1;

    Healthy subjects without hepatic impairment:

  11. Must be in good health as determined by screening medical history, physical examination, vital signs, blood chemistry, hematology, glucose, and coagulation performance at Screening;
  12. Has a negative screen for (HBV) and (HCV); and
  13. Should be matched to a subject with hepatic impairment in gender, age, and BMI.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the course of the study;
  2. Has a history or current evidence of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, neurological, or psychiatric disease that may pose a significant safety risk or diminish a subject's ability to undergo all study procedures and assessments;
  3. Evidence of renal impairment with a of \<50 mL/min/1.73m2 as measured by the Cockcroft Gault formula;
  4. Use of another drug or device within 30 days prior to receiving eravacycline (TP-434), or within at least 5 half-lives of the previous investigational drug, whichever is longer;
  5. Has a history of alcoholism or drug abuse within 2 years prior to dosing;
  6. Has a typical weekly alcohol consumption of 14 alcoholic drinks. One drink is defined as 1 glass of beer (approximately 10 oz to 12 oz) or 1 can (12 oz) of beer, 1 glass of wine (approximately 4 oz to 5 oz), or 1 glass of distilled spirits (hard liquor) containing 1 oz of the liquor (1 oz of liquid is approximately 30 mL);
  7. Use of alcohol within 48 hours prior to dosing;
  8. Has had a major surgical procedure within 3 months prior to administration of study drug;
  9. Has known allergies to tetracycline antibiotic or related compounds, or a history of multiple adverse drug allergies of any origin;
  10. Has inadequate venous access;
  11. Donated >500 mL of blood within 2 months prior to Screening;
  12. Has a change in dose or frequency of any new or chronic dose-adjusted prescription or non-prescription medication, including vitamins or herbal medications, within 7 days or 5 half-lives (if known), whichever is longer, within 2 weeks prior to dosing;
  13. Is a member of the clinical site personnel directly affiliated with this study;
  14. Has poor mental function or any other reason to expect subject difficulty in complying with the requirements of the study in the judgment of the investigator;
  15. Fails to comply with protocol requirements, or whose further participation in the study would be unsuitable to the subject, as determined by the investigator;
  16. Clinically significant abnormal (ECGs) ( or QTcF >500 msec);

    Subjects with hepatic impairment:

  17. Has active or and is receiving antiviral therapy (either prescribed or herbal);
  18. Has fluctuating or rapidly deteriorating hepatic function as indicated by clinical and/or laboratory signs of hepatic impairment (advanced ascites, infection of ascites, fever, or active gastrointestinal bleeding);
  19. Has sodium levels 125 mmol/L;
  20. Has \<40,000 × 109/L of blood or evidence of severe active or recent bleeding;
  21. Has encephalopathy, as judged by the investigator, or significant central nervous system disease (eg, dementia or seizures) which the investigator considers to interfere with , conduct, completion, or results of this study, or constitutes an unacceptable risk to the subject;
  22. Has signs of active infection;
  23. Has experienced esophageal variceal bleeding within the past 6 months;
  24. Has a Transjugular Intrahepatic Portosystemic Shunt placement;

    Subjects without hepatic impairment:

  25. Has or alanine aminotransferase >1.5 × (ULN); alkaline phosphatase or 1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). A single repeat is allowed for eligibility determination;
  26. Has systolic blood pressure outside of the range of 90-160 mmHg, or diastolic blood pressure outside the range of 45-100 mmHg, or heart rate outside the range of 50-100 bpm for female subjects or 45-100 bpm for male subjects;
  27. Has a history of Gilbert's disease; or
  28. Takes any concomitant medication, either prescribed or over-the-counter. This includes use of any prescription or non-prescription medication, including vitamins or herbal medications, within 7 days or 5 half-lives (if known), whichever is longer, prior to dosing and within 24 hours after dosing, excluding hormonal . The use of acetaminophen, naproxen, and ibuprofen is permitted except for within 24 hours prior to dosing.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Impaired hepatic function

    A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each hepatically impaired subject.

    Drug: eravacycline

  • Experimental
    Healthy subjects

    A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each healthy subject.

    Drug: eravacycline

Interventions

  • Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.

    Also known as: TP-434

06

What researchers measure

Primary outcomes

  1. This study is being conducted to assess the pharmacokinetic (PK) profile of eravacycline

    To assess the pharmacokinetic (PK) profile of eravacycline after administration of a single intravenous (IV) dose (1.5 mg/kg) to subjects with mild, moderate, and severe impaired hepatic function compared with normal healthy subjects

    Time frame: one year

Secondary outcomes

  1. Safety and tolerability of Eravacycline

    To determine the safety and tolerability of eravacycline after administration of a single IV dose (1.5 mg/kg) in subjects with mild, moderate, and severe impaired hepatic function compared with normal healthy subjects.

    Time frame: one year

07

Study locations

3 sites
  • Davita Clinical Research
    Lakewood, Colorado 800228, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee 37920, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Feb 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2014
First posted
May 9, 2014
Start
Oct 2013
Primary completionActual
Feb 2014
CompletionActual
Mar 2014
Last update
Dec 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02135302
Lead sponsor
Tetraphase Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 9, 2014
Start date
Oct 2013
Primary completion
Feb 2014
Completion
Mar 2014
Last update
Dec 17, 2021

Study contacts

William Smith, MD
principal investigator · New Orleans Center for Clinical Research
Thomas Marbury, MD
principal investigator · Orlando Clinical Research Center
Chris Galloway, MD
principal investigator · Davia Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eravacycline

Start the discussion